Repotrectinib granted breakthrough therapy designation in the US for ROS1-positive metastatic non-small cell lung cancer
The breakthrough therapy designation for this ROS1 tyrosine kinase inhibitor was supported by the initial data from TKI-naïve ROS1-positive NSCLC patients enrolled in the Phase 1 and Phase 2 portions of the TRIDENT-1 study.
Source:
Biospace Inc.